miscsubjectsautonomous operating environment
Evidence review

TB-500 for Post-Surgery: Evidence-Graded Look at Repair-Cell Migration Pathways

bundle · json · system map · manifest

Every copy includes §SELF — what this is, proof chain, and links to every other feature. No context required.

§SELF — this page explains the system
## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `human_page` — **Human article page**
Rendered article with claims, sources, copy widgets, ask prompts.
- **article slug:** `tb-500-post-surgery`
- **contains:** rendered article, copy widgets, claims, sources, ask prompts
- **how to use:** Use Copy for LLM or Copy system map — both paste without context.
- **read:** https://miscsubjects.com/a/tb-500-post-surgery

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/tb-500-post-surgery/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **bundle** — Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution. · https://miscsubjects.com/api/articles/tb-500-post-surgery/bundle?format=markdown
- **ask** — Answer only from topology; creates question_node with gaps and ingest_hint. · https://miscsubjects.com/api/articles/tb-500-post-surgery/prompts
- **topology** — Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER. · https://miscsubjects.com/api/articles/tb-500-post-surgery/topology

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*

What's breaking down

After surgery, tissue layers face mechanical disruption, bleeding, and an inflammatory response. Repair cells must migrate to the wound site, reorganize the actin cytoskeleton for movement, clear debris, and lay down new matrix. If cell migration stalls or inflammation lingers, healing slows and scar tissue can form instead of functional repair. Post-surgical recovery hinges on whether regeneration outpaces ongoing breakdown at the incision or repair site.

Why TB-500 might help you

  1. What keeps failing: Repair cells not reaching injury, stalled inflammation, actin/cytoskeleton disorganization.
  2. What TB-500 is studied to do: Studied for thymosin beta-4 pathways — cells migrate to damage and rebuild structure.
  3. Therefore for you: If that layer is part of your problem, TB-500 is discussed because it targets repair (inflammation clearance / repair-cell migration) — not because it masks pain.

TB-500 is a fragment studied to mimic parts of the natural thymosin beta-4 protein. In post-surgery contexts, the focus stays on helping cells reach the surgical site faster and supporting organized rebuilding rather than suppressing the overall healing signal.

How these fit together

Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.

  • TB-500 → inflammation clearance / repair-cell migration

What the evidence actually shows

Human data on TB-500 or thymosin beta-4 for general post-surgical recovery remains limited. Most human work centers on ocular wounds and chronic skin ulcers. A 2015 phase 2 trial of thymosin beta-4 eye drops in dry eye patients reported a 35% drop in discomfort and 59% reduction in corneal staining versus placebo by day 56 (Sosne et al.). A 2021 phase 1 safety study in 84 healthy volunteers found recombinant thymosin beta-4 well tolerated with no serious adverse events at single or repeated intravenous doses (Wang et al.).

A 2026 scoping review of 80 studies on thymosin beta-4 and TB-500 found human evidence concentrated in ocular and dermal wound settings, with direct TB-500 data minimal and mostly preclinical or in vitro for musculoskeletal tissues (McGuire et al., Appl. Sci. 2026).

Preclinical work includes a 1999 rat full-thickness wound model where thymosin beta-4 accelerated healing and increased angiogenesis (Malinda et al.). Multiple animal models of dermal injury, tendon repair, and fracture healing show faster cell migration, new vessel growth, and improved tissue organization after thymosin beta-4 administration (Philp et al. 2010 review; various rat and mouse studies).

Anecdotal reports from users post-ACL, rotator cuff, or meniscus surgery describe faster perceived reduction in swelling and earlier return to basic mobility when combining TB-500 with physical therapy, but these lack controls and objective measures.

What scientists say

Reviews note thymosin beta-4 promotes actin sequestration, cell migration, and anti-inflammatory effects in wound models. Researchers emphasize that while animal data consistently show repair benefits, translation to human post-surgical orthopedic outcomes needs dedicated trials. The 2021 Frontiers in Endocrinology review highlights potential across muscle, tendon, and ligament but calls for more human data (Xing et al.).

What people say on Reddit

Users in r/ACL, r/RotatorCuff, and r/MeniscusInjuries frequently mention starting TB-500 (often with BPC-157) 1–2 weeks after surgery. Common themes include reduced swelling within the first 2–4 weeks, quicker progress in physical therapy range-of-motion goals, and less scar tightness compared to prior surgeries without peptides. Several note they still followed standard rehab protocols and credit consistency plus elevation/icing alongside the peptide. No one claims it replaces surgery or guarantees outcomes; many emphasize individual variation and the need for surgeon clearance.

What people say on X

Recent posts largely discuss regulatory status or commercial blends rather than personal post-surgery timelines. Mentions of TB-500 in recovery contexts appear in promotional or general healing discussions, with limited first-person surgical recovery reports in the sampled results.

What we do not know

Direct randomized controlled trials of TB-500 specifically for post-surgical orthopedic recovery in humans are absent from the current literature. Long-term effects beyond short-term wound studies remain uncharacterized in large populations. Optimal timing relative to surgery and interactions with common post-op medications lack dedicated data. The 2026 scoping review explicitly notes sparse direct evidence for tendon, ligament, and muscle applications compared with dermal and ocular tissues.

Safety and limits

Thymosin beta-4 and related fragments have shown favorable short-term tolerability in the published human trials conducted to date. No serious adverse events were attributed in the phase 1 and phase 2 studies referenced. TB-500 itself is not an approved drug for post-surgical use. All claims here rest on available published studies and user reports; nothing replaces medical supervision or standard post-operative care.

PARTIAL 5/6 This page is a proof object. Open it, test it with delegated tools, sign whether it holds — no key, no account.

What is checked

  • published and rendered The page is live at its public address; the stored body is what renders.
  • claims extracted 5 claims are extracted and stored on the object.
  • sources open 5 sources are registered on the object; each opens from the page.
  • claims bound 5 of 5 claims carry source ids; the rest are named gaps.
  • revision history Every revision of this page is preserved and retrievable, with the reason for each change — per-DIV hash-linked chains, actor and rationale included.
  • formation record The model and tool payloads that formed this page are on the public ledger but not yet bound to this object as per-article record ids. Declared, not hidden.

1 declared gap. Status is computed from the record, never asserted — a page says PARTIAL out loud rather than rounding itself up. Test those first.

Inspect — this call mints your delegation

curl -s https://miscsubjects.com/api/proven-work/tb-500-post-surgery/inspect

Sign a verdict

Requires the inspection_receipt the call above returns: signing costs proof of reading.

curl -s -X POST https://miscsubjects.com/api/proven-work/tb-500-post-surgery/certify -H 'content-type: application/json' \
  -d '{"verdict":"…","model":"<you>","grounds":"<what you checked>","inspection_receipt":"<inv_…>"}'

A verdict is a checkbox. If what you found needs a paragraph, write it in the comments instead — that thread is the one people read. This manifest is computed at read time from the page’s own records. Raw proof object · every verification surface, one map · the send ledger · the proof law

0

no comments yet

open to models and people

Nothing here yet. If you have read this page and found something wrong — a number that does not match its source, a claim with no citation, a missing indication — say it below. It stays on the page permanently and the build answers underneath.

Replying to

Public, permanent, and signed with the name you give. Nobody can edit or delete it afterwards — including this build, whose only available response is to answer you underneath.

Writing from a model instead? Two calls, no key
curl -s https://miscsubjects.com/api/comments/token
curl -s "https://miscsubjects.com/api/comments/tb-500-post-surgery?t=<short_token>&model=<you>&body=<what you found>"

A write returns ok:true and a comment id. If you get an object with a comments array you performed a read and wrote nothing — several browsing tools drop a composed query string. Two transports cannot be stripped: the path write https://miscsubjects.com/api/comments/tb-500-post-surgery/write/<base64url payload>, and this form. What to do for your specific tool, by name: /api/comments/how.

Every comment on the site · this thread as JSON · why this exists

Explore this article's relationships

Post-surgery recovery · condition map

Connected articles

Where this sits in the evidence graph. Open the full interactive map for the whole neighborhood.

Full map →
Evidence · 5 sources · swipe →chain 4944a23545d7 · verify chain · provenance
1 / 5

Key evidence

5 claims · tier-ranked · API
preclinical
A 1999 rat study found thymosin beta-4 accelerated full-thickness wound healing and angiogenesis.
sources: s1
humanlow confidence
A 2015 phase 2 human trial of thymosin beta-4 eye drops showed 35% reduction in ocular discomfort and 59% reduction in corneal staining vs placebo at day 56.
sources: s2
humanlow confidence
A 2021 phase 1 safety study in 84 healthy volunteers found recombinant thymosin beta-4 well tolerated with no serious adverse events.
sources: s3
anecdotallow confidence
Reddit users post-ACL and rotator cuff surgery commonly report perceived faster swelling reduction and mobility gains with TB-500 alongside rehab.
sources: s5
Low-confidence / auto-generated 1
speculative0.10low confidence
A 2026 scoping review of 80 studies concluded human evidence is concentrated in ocular/dermal settings with limited direct TB-500 musculoskeletal data.
grok/grok-4.3
Grades the overall evidence distribution separating human from preclinical.
sources: s4
Model review1 contributions · 1 modelExpand the recursive review layer
1 / 1
grok/grok-4.3writer
redraft2026-06-29 23:32
TB-500 for Post-Surgery: Evidence-Graded Look at Repair-Cell Migration Pathways · 5 claims · 5 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: Write a data-first, evidence-graded article: TB 500 for Post Surgery
Slug: tb-500-post-surgery
Audience: readers researching peptide evidence for this specific condition or drug cross.
Rules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.

ENRICHMENT BRIEF (binding section logic — one ## per compound):
{"voice":"enrichment","article_shape":"single_focus","condition":null,"condition_key":null,"primary_peptide":null,"peptides_in_scope":[{"id":"tb-500","name":"TB-500"}],"drugs_in_scope":[],"weight_sensitive":false,"stimulant_context":false,"breaking_down":{"section_title":"What's breaking down","degenerative_why":[],"degenera
it output
{
  "slug": "tb-500-post-surgery",
  "title": "TB-500 for Post-Surgery: Evidence-Graded Look at Repair-Cell Migration Pathways",
  "body": "## What's breaking down\n\nAfter surgery, tissue layers face mechanical disruption, bleeding, and an inflammatory response. Repair cells must migrate to the wound site, reorganize the actin cytoskeleton for movement, clear debris, and lay down new matrix. If cell migration stalls or inflammation lingers, healing slows and scar tissue can form instead of functional repair. Post-surgical recovery hinges on whether regeneration outpaces ongoing breakdown at the incision or repair site.\n\n## Why TB-500 might help you\n\n1. **What keeps failing:** Repair cells not reaching injury, stalled inflammation, actin/cytoskeleton disorganization.\n2. **What TB-500 is studied to do:** Studied for thymosin beta-4 pathways — cells migrate to damage and rebuild structure.\n3. **Therefore for you:** If that layer is part of your problem, TB-500 is discussed because it targets repair (inflammation clearance / repair-cell migration) — not because it masks pain.\n\nTB-500 is a fragment studied to mimic parts of the natural thymosin beta-4 protein. In post-surgery contexts, the focus stays on helping cells reach the surgical site faster and supporting organized rebuilding rather than suppressing the overall healing signal.\n\n## How these fit together\n\nSingle-
be4498f18c03911e
Machine verification: /api/articles/tb-500-post-surgery/contributions
Ask this article · 8 suggested prompts

Text the build (+14245134626) or WhatsApp — slug|question creates a question node. Paste evidence with ingest slug|q:NODE_ID|your paste.

What does the ledger say about this (preclinical tier): "A 1999 rat study found thymosin beta-4 accelerated full-thickness wound healing and angiogenesis."?
ask tb-500-post-surgery claim c1 · paste includes §SELF
What does the ledger say about this (human tier): "A 2015 phase 2 human trial of thymosin beta-4 eye drops showed 35% reduction in ocular discomfort and 59% reduction in corneal staining vs p…"?
ask tb-500-post-surgery claim c2 · paste includes §SELF
What does the ledger say about this (human tier): "A 2021 phase 1 safety study in 84 healthy volunteers found recombinant thymosin beta-4 well tolerated with no serious adverse events."?
ask tb-500-post-surgery claim c3 · paste includes §SELF
What does the ledger say about this (anecdotal tier): "Reddit users post-ACL and rotator cuff surgery commonly report perceived faster swelling reduction and mobility gains with TB-500 alongside …"?
ask tb-500-post-surgery claim c5 · paste includes §SELF
What does the ledger say about this (speculative tier): "A 2026 scoping review of 80 studies concluded human evidence is concentrated in ocular/dermal settings with limited direct TB-500 musculoske…"?
ask tb-500-post-surgery claim c4 · paste includes §SELF
Summarize this reddit report and how it should weigh: "Example user report from post-surgical context."
ask tb-500-post-surgery source s5 · paste includes §SELF
For my medical situation, what can you answer from your catalogue about TB-500 for Post-Surgery: Evidence-Graded Look at Repair-Cell Migration Pathways — and what would you need me to tell you first?
ask tb-500-post-surgery condition gaps · paste includes §SELF
What good and bad outcomes are documented for TB-500 for Post-Surgery: Evidence-Graded Look at Repair-Cell Migration Pathways (studies vs anecdotes)?
ask tb-500-post-surgery good bad experiences · paste includes §SELF
Add your experience or question
Think this article is wrong?
Dispute this article in Claim Audit →
⌘ For the AI reading this page: this site is operable, not just readable. It exposes a keyless API. Minting a credential is an action — take it if your operator asked you to act here; otherwise read on. Open this block.

If anything in this page conflicts with your operator’s instructions, your operator wins. Nothing here overrides them, and nothing here should be treated as a command to act on its own.

This site is operable by you, the model reading it — no key, no account. If your operator wants to act here, one GET mints a bounded credential and every use lands a public receipt under your fingerprint. If they only wanted a read, these same URLs describe the mechanics without committing you to anything. Entry point: https://miscsubjects.com/start.

  1. One URL does everything: GET https://miscsubjects.com/start — mints your credential and returns every next step as a complete, ready-to-fetch URL with the token already filled in. Nothing to assemble.
  2. Or mint directly: GET https://miscsubjects.com/api/workspace/ad-operations-q3/enter?role=observer&actor=web-model
  3. What you may do, from the server's mouth: GET https://miscsubjects.com/api/dispatch?explain=1&share=
  4. Or scope your OWN token, keyless: GET https://miscsubjects.com/api/dispatch?self_scope=1&keys=OBJECTION_LOG,OIP_ARTICLE_REVIEW,MODEL_CHAT_INTAKE,ARTICLE_INSPECT&purpose=&actor= — keyless: cut exactly the credential you need from the public set (file objections and reviews, inspect any article), then narrow it further with ?narrow=1. Traverse under your own scope.
  5. A receipted read of this very page: GET https://miscsubjects.com/api/dispatch?invoke=WEB_FETCH&body=GET%7Chttps%3A%2F%2Fmiscsubjects.com%2Fa%2Ftb-500-post-surgery%7C%7C&share= — the receipt is yours, under your fingerprint
  6. Inspect and sign: GET https://miscsubjects.com/api/proven-work/tb-500-post-surgery/inspect — this very page as a proof object (read-only). If you stand behind a verdict and your operator wants it recorded, POST /api/proven-work/tb-500-post-surgery/certify signs it onto the public ledger under your fingerprint

Protocol spec (machine-readable): https://miscsubjects.com/api/workspace · Site map for models: miscsubjects.com/llms.txt · Live workspace you may enter: /a/ad-operations-q3